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Introduction
The pancreas in a non-diabetic patient constantly secretes a small amount of insulin (basal secretion). After meals, a larger 
amount of insulin is secreted (bolus secretion) to cope with the increased blood glucose that occurs following a meal. 
The goal of insulin therapy in diabetics is to mimic this secretion pattern to provide enough insulin throughout a 24-hour 
period to meet the basal requirements and to deliver higher boluses of insulin to meet the glycaemic effect of meals. To 
achieve good diabetes control, an individually tailored insulin treatment regimen is required.
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TYPES OF INSULIN
Insulin was discovered in 1921 by Dr 
Frederick G Banting and Charles Best. 
It was first administered to a patient in 
1922 and, since then, has been com-
mercially available for the treatment of 
diabetes mellitus. Significant develop-
ments in insulin research have been the 
advent of recombinant DNA techniques 
and devices, allowing for easier admin-
istration of insulin. 
Recombinant DNA technology has 
provided the means to produce large 
amounts of insulin identical to human in-
sulin, thus eliminating the need to obtain 
insulin from animal sources (beef and 
pig). The various types of insulin differ 
in their pharmacokinetic profiles (Table 
I). The following discussion has been 
limited to human insulin, as it is readily 
available in South Africa. 
Conventional insulin
Regular (soluble)
This form of insulin consists of zinc 
crystals that self-associate into dimers 
and then hexamers after subcutane-
ous injection. The hexameric form is 
more slowly absorbed, thereby delay-
ing the onset of action (see Figure 1 A). 
Examples are Actrapid (Novo Nordisk) 
and Humulin R (Lilly). 
Neutral protamine Hagedorn (NPH)
These insulins are crystalline suspen-
sions of regular insulin complexed with 
protamine and zinc (NPH). This complex 
has a delayed absorption, thus delaying 
the onset of action and providing an 
intermediate-acting insulin (see Figure 
1 B). Isophane NPH insulins are exten-
sively used in children, mainly because 
of their suitability for mixing with soluble 
insulin. The pharmacokinetic profiles of 
these insulins make them suitable for 
twice-daily regimens and for the pre-
bedtime dosage in basal bolus and 
three-times daily regimens. Examples 
are Protophane and Humulin N.
Lente and Ultralente
These preparations are complexed 
with zinc crystals only. As with NPH, 
the complex has a delayed absorption, 
thus delaying the onset of action and 
providing an intermediate-acting insulin. 
These preparations have largely been 
superseded by the longer-acting insulin 
analogues.
Premixed insulin
These are fixed ratio mixtures of soluble 
and isophane (NPH) insulins. They are 
useful in adults and pre-pubertal chil-
dren, particularly when compliance is 
a problem. There is evidence of poorer 
metabolic control in adolescents using 
these insulins, as they remove the flex-
ibility offered by separate adjustments 
of the two types of insulin.
Insulin analogues
Recombinant DNA technology, as well 
as the wish to emulate normal insulin 
secretion, has led to the development 
of analogues to human insulin.1 These 
analogues are comparable to con-
ventional insulin in their ability to bind 
the insulin receptor; however, due to 
modifications in the β- and/or α-chain 
of the insulin molecule, the insulin ana-
Table I: Pharmacokinetics of the various types of insulin
Insulin Source Onset Peak Duration
Rapid-acting
Analogues
      Insulin Lispro (Humalog) Recombinant DNA 15 mins 60 mins 3-4 hours
      Insulin Aspart (NovoRapid) Recombinant DNA 10 mins 45 mins 3-5 hours
      Insulin Glulisine (Apidra) Recombinant DNA 50-60 mins 3-4 hours
Regular (soluble)
      Actrapid Recombinant DNA 30 mins 2.5-5 hours 8 hours
      Humulin R Recombinant DNA 20-30 mins 1-3 hours 5-7 hours
Intermediate-acting
      Protophane Recombinant DNA 90 mins 4-12 hours 18-24 hours
      Humulin N Recombinant DNA 60 mins 2-8 hours 18-20 hours
Long-acting
      Glargine (Lantus) Recombinant DNA 1-2 hours No peak 20-24 hours
      Detemir (Levemir) Recombinant DNA 30-60 mins No peak 20-24 hours
Pre-mixed
      Humulin 30/70 Recombinant DNA 30 mins 1-8 hours 14-15 hours
      Actraphane Recombinant DNA 30 mins 2-12 hours 16-24 hours
      Humalog Mix 75/25 Recombinant DNA 5-15 mins Dual 10-16 hours
      NovoLog Mix Recombinant DNA 5-15 mins Dual 10-16 hours
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logues differ from conventional insulin 
in their pharmokinetic profiles. All insulin 
analogues approved for clinical use are 
comparable to conventional insulins with 
respect to their safety profiles and ability 
to induce antibody production.
Rapid-acting
Manipulation of amino acids in the 
β-chain of insulin has resulted in the 
development of three ultra-short-act-
ing insulin analogues, namely insulin 
lispro (Humalog, Eli Lilly), insulin aspart 
(NovoRapid, Novo Nordisk) and insulin 
glulisine (Apidra, Sanofi Aventis). Insulin 
lispro was developed by the reversal of 
amino acids proline (position 28) and 
lysine (position 29); insulin aspart was 
formed by the substitution of proline (po-
sition B28) with aspartic acid; and insulin 
glulisine was developed by substitution 
of asparagine (position 3) with lysine 
and lysine (position 29) with glutamic 
acid. These alterations have resulted in 
insulin molecules with a decreased abil-
ity to self-associate, thereby increasing 
the absorption rate. As a consequence, 
the onset of action is more rapid and the 
duration of action is reduced (see Fig-
ure 1 C). Regimens using rapid-acting 
analogues have been shown to induce a 
small but significant reduction in HbA1c 
and comparable results in overall hypo-
glycemia when compared to regimens 
using regular insulin.2,3 The use of these 
analogues was shown to improve quality 
of life, largely due to the shorter interval 
between insulin administration and eat-
ing. In children they offer the option of 
being given after meals, particularly in 
toddlers who are reluctant to eat. Of 
note is that there currently is no long-
term efficacy and safety data for the 
use of these agents and therefore they 
should be used cautiously.2
Long-acting
In an attempt to develop an insulin that 
can best provide a 24-hour predictable 
and stable basal level without peaks 
and troughs, recombinant DNA tech-
niques have been used to develop insu-
lin glargine (Lantus, Sanofi Aventis) and 
insulin detemir (Levemir, Novo Nordisk). 
Studies comparing the use of these 
agents with NPH insulin have shown no 
significant improvement in HbA1c, but 
some studies have shown a reduction in 
hypoglycaemic events (especially noc-
turnal hypoglycaemia).4,5,6 The results 
of studies in children and adolescents 
using long-acting insulin analogues are 
comparable to those of adults.7 
Insulin glargine: This analogue was 
formed by the addition of two arginine 
residues to the C-terminal end of the 
β-chain of insulin, as well as the substi-
tution of asparagine (position 21 of the 
-chain) with glycine. This insulin mol-
ecule is less soluble at physiological pH 
levels and therefore precipitates once 
injected into the subcutaneous tissues. 
This delays absorption and increases 
the duration of action. The net clinical 
effect is a single daily injection that 
provides a glucose-lowering effect for 
24 hours without a pronounced plasma 
peak (see Figure 1 D). 
Insulin detemir: The addition of a fatty 
acid to the insulin molecule enables 
binding to albumin. As albumin has a 
slow disappearance rate from the sub-
cutaneous tissues, there is a delay in 
the absorption of this insulin molecule, 
thereby prolonging its duration of ac-
tion.   
INSULIN REGIMENS
There is convincing evidence that de-
creasing the HbA1c to < 7% in patients 
with type 1 diabetes mellitus prevents 
or delays the onset of microvascular 
(retinopathy, neuropathy, nephropathy) 
complications.8,9,10,11 Furthermore, any 
decrease in the HbA1c concentration 
is associated with a decline in the rela-
tive risk of microvascular complications. 
The DCCT/EDIC cohort has shown that 
a period of good glycaemic control 
can reduce long-term macrovascular 
disease.12 Thus, the clinician should 
strive to decrease the HbA1c, targeting 
a value of < 7% but bearing in mind that 
any decrease in the HbA1c translates 
into a decreased risk of complications. 
Unfortunately, as the HbA1c decreases 
towards the target value, the risk of 
hypoglycaemic episodes increases. 
This necessitates that the treating clini-
cian choose a therapeutic regimen that 
realises the target HbA1c with minimal 
hypoglycaemic episodes. Insulin ther-
apy is the mainstay of treatment, with 
various types of insulin and insulin dos-
ing regimens from which to choose. The 
array of choice often creates uncertainty 
amongst clinicians, but the following ba-
sic principles are suggested:
1) Individualise therapy
2)  Start with the simplest regimen with 
which your patient will be compliant
3)  Aim for an HbA1c under 7% (in some 
cases this may not be achievable, as 
significant hypoglycaemic episodes 
may occur when approaching this 
target)
4)  “Start low and go slow”, avoiding 
hypoglycaemic episodes that are 
dangerous and serve to undermine 
the confidence of your patient with 
the specific insulin regimen
5)  Regular glucose monitoring is es-
sential (rule of thumb: patients should 
check their blood glucose before 
every insulin injection)
Prior to commencing insulin therapy, it is 
advisable that children be assessed by 
a specialist paediatrician or at a centre 
dedicated to managing children with 
diabetes mellitus.
1) Basal bolus regimen
Rationale: strives to mimic normal 
physiology by providing a rapid-act-
ing insulin prior to each meal, thereby 
reducing postprandial glucose peaks, 
and an intermediate to long-acting in-




Given at time-point A (Figure 1 A) before 
breakfast, lunch and supper. 
•  Public sector – usually only have ac-
cess to rapid-acting regular human 
insulin (Actrapid and/or Humulin R). 
This insulin should be given 30 min-
utes prior to meals.
•  Private sector – access to rapid-act-
ing regular human insulin as well as 
the insulin analogues (insulin lispro, 
insulin aspart and insulin glulisine). 
These can be given 10 to 15 minutes 
prior to a meal or with a meal. Since 
these have a more rapid onset of 
action, their peak effect coincides 
with the postprandial glucose peak, 
thereby decreasing postprandial hy-
poglycaemic episodes. To children 
they are usually given with a meal 
and sometimes afterwards, espe-
cially to toddlers.
 Intermediate / long-acting insulin
Given at time point B (Figure 1 A) at 
22h00.
•  Public sector – Protophane and/or 
Humulin N
•  Private sector – Protophane, Humulin 
N, insulin glargine (Lantus), insulin 
detemir (Levemir)
This insulin dose provides a basal level 
over 18 to 24 hours. Since there is a 
significant amount of insulin present at 
a time when the patient is sleeping and 
not eating, a pre-sleep snack is impor-
tant to decrease nocturnal hypoglycae-
mia. Lantus and detemir do not have a 
peak and provide a “smoother” insulin 
profile, thereby decreasing hypogly-
caemic episodes, especially those that 
occur at night.
A snack should be eaten before sleep 
to prevent potential hypoglycaemia that 
occurs when the intermediate-acting in-
sulin is peaking in the early hours of the 
morning (time-point C, Figure 2).
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Figure 2: Basal bolus insulin regimen
Starting dose: 
Adults
units of insulin / day = 0.3 x body weight (kg) 
 60% given as rapid-acting insulin
  40% given as intermediate to long-
acting insulin
Children
units of insulin / day = 0.6 x body weight (kg)
 50-70% given as rapid-acting insulin
  30-50% given as intermediate to 
long-acting insulin
Prepubertal children usually require 0.6-
1.0 u insulin/kg/day, but during puberty 
the insulin requirements may rise sub-
stantially above 1.0 u/kg/day.13
Patients should monitor their blood 
glucose prior to each insulin dose and 
can be taught to adjust their insulin dos-
age according to their blood glucose 
reading, thereby decreasing risks of 
hyperglycaemia and hypoglycaemia.
Which patient?
This regimen requires multiple blood 
glucose monitoring and multiple injec-
tions daily and will best suit a patient that 
is motivated, has insight into their illness, 
can tolerate multiple needle-sticks, and 
is able to carry their glucometer and in-
sulin with them during the day. An add-
ed advantage with this regimen is that 
the insulin dose can be omitted if a meal 
is to be missed, although all diabetics 
should strive to eat regular meals.  
2) Bi-daily regimen
Rationale: Premixed insulin containing 
a rapid-acting insulin and an intermedi-
ate to long-acting insulin. This mixture 
is given before breakfast and before 
supper. The rapid-acting insulin serves 
to decrease the postprandial glucose 
peak occurring after breakfast and sup-
per, whilst the intermediate to long-act-
ing insulin provides a basal level. 
Regimen:
Premixed insulin 
Given at time points A (Figure 3) 30 min-
utes before breakfast and supper
•  Public sector - Actraphane and Hu-
mulin 30/70
•  Private sector - Actraphane, Humulin 
30/70, Humalog Mix25 and NovoMix 
30
Snacks should be eaten at time points B 
(see Figure 3) to prevent daytime hypo-
glycaemic episodes, as the insulin levels 
are still high relative to the postprandial 
serum blood glucose level at those time 
points. An additional snack should be 
taken before sleep (time point C, Figure 
3) to prevent potential hypoglycaemia 
that occurs when the intermediate-act-
ing insulin is peaking in the early hours 
Figure 1: A rapid-acting regular (soluble) insulin, B NPH insulin, C rapid-acting insulin ana-
logues, D long-acting insulin analogues





































































of the morning (time point D, Figure 3).
Starting dose:
Adults
units of insulin / day = 0.3 x body weight (kg) 
 66% of dose given before breakfast
 33% of dose given before supper
Children
units of insulin / day = 0.6 x body weight (kg)
 66% of dose given before breakfast
 33% of dose given before supper
  This dose will be adjusted accor-
ding to weight and pubertal stage, 
as indicated previously.
Which patient?
This regimen is more applicable to the 
patient who is less motivated, cannot 
tolerate multiple needle-sticks and will 
not have access to their glucometer 
and insulin during the day. An addi-
tional disadvantage of this regimen is 
the necessity to have regular snacks at 
mid-morning, mid-afternoon and mid-
evening, to decrease the likelihood of 
hypoglycaemic episodes.
3) Three-times-a-day regimen
Rationale: If the insulin given with 
supper in the bi-daily regimen does 
not last until morning, then the rapid-
acting component should be given 
before supper and the intermediate 
to long-acting component should be 
postponed until just before bedtime. 
This is particularly useful in children, as 
it decreases the risk of nocturnal hypo-
glycaemia and the dawn phenomenon 
(hyperglycaemia prior to awakening).
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Regimen:
Premixed insulin (see bi-daily regimen)
Given at time point A (Figure 4) 30 min-
utes before breakfast. 
The rapid-acting and intermediate-act-
ing insulins can be also be given indi-
vidually to individualise doses.
Rapid-acting insulin (see basal bolus 
regimen)
Given at time point B (Figure 4) before 
supper. 
 Intermediate / long-acting insulin (see 
basal bolus regimen)
Given at time point C (Figure 4) at 
21h00 to 22h00.
Snacks should be eaten at time points 
D to prevent daytime hypoglycaemic 
episodes, as the insulin levels are still 
high relative to the postprandial se-
rum blood glucose level at those time 
points. An additional snack should be 
taken before sleep (time point E, Figure 
4) to prevent potential hypoglycaemia 
that occurs when the intermediate-act-
ing insulin is peaking in the early hours 
of the morning (time point F, Figure 4). 
4) Insulin infusion pump
This is probably the gold standard 
form of therapy, but it is expensive and 
beyond the affordability of the majority 
of patients. The rationale for its use is 
similar to that of the basal bolus regi-
men. Using the pump, patients receive 
a continuous basal level of insulin and a 
bolus dose prior to each meal. The bo-
luses can be programmed or performed 
manually. 






































Figure 4: Three-times-a-day regimen
CONCLUSION
The suggested insulin regimens are a 
safe way to initiate insulin treatment, but 
no insulin regimen satisfactorily mimics 
the normal physiology and no regimen 
can be optimised without individualis-
ing therapy and frequent assessment 
through blood glucose monitoring.
USEFUL INTERNET WEBSITES
•  International Society for Pediatric 
and Adolescent Diabetes (ISPAD) 
(www.ispad.org)
•  ISPAD consensus guidelines for the 
management of type 1 diabetes in chil-
dren and adolescents (www.ispad.org)
•  American Diabetes Association 
(www.diabetes.org/home.jsp)
•  South African National Diabetes Guide-
lines (www.semdsa.org.za)
•  Patient information (www.diabetes.nidd
k.nih.gov/ )
• Patient information (www.diabetes.com) 
See CPD Questionnaire, page 48
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